Evidence-Based Products

STUDY CLAIM: 80.4mg/day soy isoflavones may reduce bone loss from the lumbar spine in perimenopausal women.

PUBLISHED: Alekel DL, et al. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 2000;72:844-52.

ABSTRACT: Researchers at Iowa State University examined the effects of consuming 80.4mg/day soy protein isolate with isoflavones for 24 weeks for the purpose of attenuating bone loss during menopause. They randomly selected 69 perimenopausal women for double-blind treatment: isoflavone-rich soy (SPI+; n = 24), isoflavone-poor soy (SPI-; n = 24), or whey (control; n = 21) protein. Lumbar spine bone mineral density (BMD) and bone mineral content (BMC) were measured at baseline, mid-treatment and post-treatment.

The percentage change in lumbar spine BMD and BMC did not differ from zero in the SPI+ or SPI- groups, but loss did occur in the control group (-1.28 per cent, p = .0041; -1.73 per cent, p = .0037). Baseline BMD and BMC negatively affected the percentage change in baseline body weight, and bone-free lean weight contributed positively to percentage change in BMD and BMC. Analysis of covariance with BMD or BMC as the outcome showed that isoflavones, not soy protein, made the difference.

POTENTIAL APPLICATIONS: SuproSoy is used in a wide array of beverages, bars, meats, baking items, soups, spreads, creamers, dairy alternatives, tofu, snacks, meat alternatives, cereals, pasta, sandwiches, yogurt and soy protein-based infant formulas.

MORE INFO: Dupont Protein Technologies, P.O. Box 88940, St. Louis, Missouri 63188 Tel: +1 800 325 7108 www.protein.com, www.solae.com

Quality of Life Labs AHCC
STUDY CLAIM: AHCC may help restore health in various organs that are affected by oxidative stress.

PUBLISHED: Shuyi W, et al. Preventive effects of active hexose correlated compound (AHCC) on oxidative stress induced by ferric nitriloriaceate. Dokkyo J Med Sci 2001;28(2-3):745-52.

ABSTRACT: Ferric nitriloriaceate (Fe-NTA) is a strong oxidant that generates highly reactive hydroxyl radicals and causes injuries to various organs, including the kidney and liver. The formation of 8-hydroxy-2-deoxyguanosine (8-OHdG) adducts in renal DNA is one of the earliest events after treatment with Fe-NTA. Because active hexose correlated compound (AHCC), an extract of fungi, exhibits antioxidant properties, researchers examined its protective effect on the oxidative stress induced by Fe-NTA.

Researchers gave 3 per cent AHCC/day in drinking water to male Wistar rats for one week, and then injected Fe-NTA intraperitoneally. Three hours after the treatment, there was a significant increase in 8-OHdG levels in the bladder, creatinine in the serum, thymic apoptosis, and serum levels of aspartate and alanine aminotransferases. All of these increases were restored to normal by the AHCC pretreatment. The results suggest AHCC may reverse the disorders of various organs induced by oxidative stressors.

POTENTIAL APPLICATIONS: AHCC may improve the quality of life for patients with cancer, AIDS, hepatitis B and C and other ailments involving immune dysfunction. It is available in 500mg capsules.

MORE INFO: Quality of Life Labs, 2700 Westchester Ave., Purchase, New York10577 Tel (toll-free): +1 877 YES AHCC, www.q-o-l.com

STUDY CLAIM: 200mg/day oral pycnogenol may lower systolic blood pressure in mildly hypertensive patients.

PUBLISHED: Hosseini S, et al. A randomised, double-blind, placebo-controlled, prospective, 16-week crossover study to determine the role of pycnogenol in modifying blood pressure in mildly hypertensive patients. Nutr Res 2001;21:1251-60.

ABSTRACT: Pycnogenol is a mixture of bioflavonoids from the French maritime pine bark extract (Pinus pinaster). Researchers conducted this study to determine the possible protective effect of oral pycnogenol on nonsmoking, slightly hypertensive patients. In a double-blind, randomised, crossover study, researchers gave 200mg/day oral pycnogenol or placebo to 11 nonsmoking, mildly hypertensive patients (seven men and four women) for eight weeks. Patients had systolic blood pressure of 140-159mmHg and/or diastolic blood pressure of 90-99mmHg.

Subjects taking pycnogenol experienced a significant decrease in systolic blood pressure, although there was no statistical significance in diastolic blood pressure when compared to placebo. Pycnogenol significantly decreased serum thromboxane in blood platelets (an increase in this serum can lead to thrombosis or blood clotting).

POTENTIAL APPLICATIONS: Pycnogenol, available in powder form for capsules and tablets, may help promote a healthy circulatory system.

MORE INFO: Horphag Research,P.O. Box 80, Avenue Louis-Casal 71 CH-1216 Cointrin, Geneva, Switzerland Tel: +41 22 710 26 26, www.pycnogenol.com

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.